Pituitary-adrenal dysfunction caused by nivolumab for head and neck cancer
{{output}}
Nivolumab exerts antitumor effects by inhibiting binding of PD-L1 to PD-1, and offers proven effectiveness in various disease areas, including cancers of the head and neck. The mechanisms of action lead nivolumab to induce immune-related adverse events (irAE).... ...
